As AI workloads push rack densities to 150 kW and beyond, data centre design is inverting – from white space outward to infrastructure inward. MEP Director Michael Hope-Jones argues the industry needs to stop chasing the future and start building present-enabling infrastructure that can adapt as requirements crystallise.

What happens when drug discovery leaders, big pharma, regulators, AI solution providers, and venture capital sit in the same room? Bryden Wood's Accelerate roundtable on AI and pharmaceutical manufacturing surfaced a clear consensus: the hype is in the wrong places – and we are not ambitious enough.

Professor John Dyson asks what it means to be human at a moment when AI is reshaping how we work, decide, and collaborate – drawing on philosophy, neuroscience, and a walk in the woods to argue that curiosity, ethics, and practical reasoning matter more now than ever.

Professor John Dyson builds an economic model to test what happens when pharmaceutical production scale gets it wrong. The results are striking – and largely ignored by industry. Understanding diseconomies of scale, he argues, could save billions and change how companies think about their entire product portfolio.

Solvents are costly, environmentally harmful, and heavily regulated – yet the pharmaceutical industry has no clear path to replacing them. This roundtable report from Bryden Wood's Accelerate Pharmaceuticals series captures what happens when the whole ecosystem comes together to confront the dilemma honestly.

Why are things the size they are? Professor John Dyson traces the logic of scale from mitochondria to mega-factories – and argues that nature solved this problem millions of years ago. The question is whether industry is paying attention.

What happens when competitors from across the data centre industry come together to share problems openly? Bryden Wood convened leaders from Google, Equinix, VIRTUS, Edged, and Digital Realty to confront the sector's most pressing challenges – from exponential rack density to power supply constraints and regulatory fragmentation across Europe.

As 2024 draws to a close, Professor John Dyson reflects on three unexpected sources of optimism – the values of the next generation, the quiet work of people already building a better world, and the profound humanity of strangers thrown together on an overcrowded train.

Two very different projects. Two FOYA awards. One unifying approach. Adam Jordan examines how Design to Value delivered award-winning outcomes for GSK in Parma and Pfizer in Singapore – and what both projects reveal about the gap between conventional briefing and genuinely value-led design.

Data centre design is too complex and too consequential to rely on intuition. Thomas Lockie and Brathepan Alagenthiran explain how Bryden Wood's Chip Thinking® approach uses digital simulation and data-driven modelling to assess performance, reduce risk, and accelerate delivery — from initial brief through to industrialised construction.

Gigafactories are among the most complex and time-critical buildings in the world. Adam Jordan, Bryden Wood's Asia-Pacific Lead, examines how DfMA can reduce cost and programme by 30% or more – and why getting the design right before prefabricating anything is the critical first step.

Laboratories underpin everything from cancer research to vaccine development – yet they remain largely invisible in conversations about industrial transformation. Bryden Wood convened leaders from across the sector to ask what the laboratory of the future looks like, and what it will take to get there.

How you reject heat is one of the most consequential decisions in data centre design – affecting PUE, water consumption, footprint, and long-term flexibility. Robin Underwood examines the options, the trade-offs, and what the shift to liquid cooling means for heat rejection systems going forward.

How do you stop a great pharmaceutical project concept from being ground down by the delivery process? In Part 2 of Pharma's Conundrum, Professor John Dyson sets out the principles of Integrated Project Delivery – and why shared value, not scope management, is the real measure of success.

The pharmaceutical industry assumes that once a project concept is agreed, iteration is a risk. Professor John Dyson argues the opposite – that emergence in design is inevitable, and that pretending otherwise destroys value. Part one of his Pharma's Conundrum series sets out a smarter approach to scheme design.

Process intensification, modularity, and automation could deliver billions in improved cash flow and drive pharmaceutical manufacturing close to net zero. So why isn't the industry moving faster? Professor John Dyson reports on what happened when four of the world's largest pharma companies came together to ask that question out loud.

Place matters more than most people think. Professor John Dyson argues that the environment where collaboration happens – its architecture, aesthetics, and culture – carries far more weight than the agenda. The Grand Hotel of Value is his answer to a problem the pharmaceutical industry hasn't yet named.

The Devil's Snare binds tighter the more you struggle. Professor John Dyson argues this is precisely what the construction and pharmaceutical industries are doing – and that the way out is not more effort in the same direction but the courage to try something genuinely different.

Personal guilt about climate change is understandable but insufficient. Professor John Dyson argues that what this moment demands is not hair shirts but the kind of leadership that built Spitfires in a Newbury carpentry workshop – ambition, ingenuity, and the determination to do things that have not been done before.

Major clients with national or global rollouts shouldn't have to start from scratch on every site. Director Jaimie Johnston MBE explains Reference Design – Bryden Wood's approach to developing a highly optimised, site-agnostic core design that can be configured, scaled, and industrialised across an entire programme.